About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Myh9tm1.1Gac
targeted mutation 1.1, Christian Gachet
MGI:3843980
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Myh9tm1.1Gac/Myh9tm1.1Gac
Tg(Pf4-icre)Q3Rsko/0
involves: 129 * C57BL/6 MGI:3844021
cn2
Myh9tm1.1Gac/Myh9+
Tg(Pf4-icre)Q3Rsko/0
involves: 129 * C57BL/6 MGI:3844022
cn3
Myh9tm1.1Gac/Myh9tm1.1Gac
Tg(NPHS2-cre)295Lbh/0
involves: 129 * C57BL/6 * SJL MGI:5432397


Genotype
MGI:3844021
cn1
Allelic
Composition
Myh9tm1.1Gac/Myh9tm1.1Gac
Tg(Pf4-icre)Q3Rsko/0
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Myh9tm1.1Gac mutation (3 available); any Myh9 mutation (226 available)
Tg(Pf4-icre)Q3Rsko mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• during bleed time experiments, mice die within 20 minutes if not cauterized manually

hematopoietic system
• platelets are twice the size as in wild-type mice
• the number of platelets is 40% of wild-type
• however, in vitro platelet half-life is normal
• some ovoid platelets are mixed in with the normal population unlike in wild-type mice
• following activation with thrombin or U46619, platelets fail to undergo spheration unlike similarly treated wild-type platelets
• activated platelets exhibit very little shape change unlike wild-type platelets
• platelets fail to exhibit retraction after thrombin activation unlike wild-type platelets
• at low concentrations of thrombin and U46619, platelets exhibit decreased aggregation compared to wild-type platelets
• following activation with thrombin or U46619, platelets fail to undergo spheration unlike similarly treated wild-type platelets
• serotonin release from dense granules is decreased after activation with U46619 or low concentrations of thrombin compared to similarly treated wild-type platelets
• activated platelets exhibit very little shape change unlike wild-type platelets
• activated platelets fail to form stress fibers unlike wild-type platelets
• however, platelet aggregation does occur

homeostasis/metabolism
• in vitro under flow conditions and in vivo, thrombus organization is impaired compared to in wild-type mice
• platelets fail to exhibit retraction after thrombin activation unlike wild-type platelets
• at low concentrations of thrombin and U46619, platelets exhibit decreased aggregation compared to wild-type platelets
• following activation with thrombin or U46619, platelets fail to undergo spheration unlike similarly treated wild-type platelets
• serotonin release from dense granules is decreased after activation with U46619 or low concentrations of thrombin compared to similarly treated wild-type platelets
• activated platelets exhibit very little shape change unlike wild-type platelets
• activated platelets fail to form stress fibers unlike wild-type platelets
• however, platelet aggregation does occur
• mice exhibit increased bleed time compared with wild-type mice
• during bleed time experiments, mice die within 20 minutes if not cauterized manually




Genotype
MGI:3844022
cn2
Allelic
Composition
Myh9tm1.1Gac/Myh9+
Tg(Pf4-icre)Q3Rsko/0
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Myh9tm1.1Gac mutation (3 available); any Myh9 mutation (226 available)
Tg(Pf4-icre)Q3Rsko mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• platelets exhibit decreased retraction after thrombin activation compared to wild-type platelets

homeostasis/metabolism
• platelets exhibit decreased retraction after thrombin activation compared to wild-type platelets




Genotype
MGI:5432397
cn3
Allelic
Composition
Myh9tm1.1Gac/Myh9tm1.1Gac
Tg(NPHS2-cre)295Lbh/0
Genetic
Background
involves: 129 * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Myh9tm1.1Gac mutation (3 available); any Myh9 mutation (226 available)
Tg(NPHS2-cre)295Lbh mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
N
• surprisingly, mice are viable and do not develop overt chronic kidney disease up to 9 months of age
• no excessive proteinuria at 1-9 months of age relative to control mice
• normal urine albumin/creatinine ratios at 3-9 months of age relative to control mice
• at 3, 4, and 6 weeks after adriamycin injection, mice develop significantly more albuminuria than similarly-treated control mice
• after adriamycin injection, mice exhibit patches of foot process fusion, unlike similarly-treated control mice
• after adriamycin injection, mice exhibit patches of severe foot process effacement, unlike similarly-treated control mice
• after adriamycin injection, mice exhibit evidence of pseudovillous transformation, unlike similarly-treated control mice
• after adriamycin injection, mice exhibit thickening of the basement membrane in some glomerular loops, unlike similarly-treated control mice
• at 6 weeks after adriamycin injection, mice develop focal and segmental glomerulosclerosis ranging from mild segmental sclerosis to severe global sclerosis, unlike similarly-treated control mice which develop foci of mild sclerosis but no globally sclerotic glomeruli
• at 6 weeks after adriamycin injection, mice exhibit numerous proteinaceous casts, unlike similarly-treated control mice

homeostasis/metabolism
N
• no excessive proteinuria at 1-9 months of age relative to control mice
• normal urine albumin/creatinine ratios at 3-9 months of age relative to control mice
• normal serum creatinine and BUN levels at 9 months of age relative to control mice
• at 3, 4, and 6 weeks after adriamycin injection, mice develop significantly more albuminuria than similarly-treated control mice
• following injection with doxorubicin hydrochloride (adriamycin; 15 ug/g) to induce kidney podocyte injury, 9-11 month old mice develop severe proteinuria and glomerulosclerosis, unlike similarly-treated control mice

growth/size/body
N
• normal body weight at 9 months of age relative to control mice

cardiovascular system
N
• no significant difference in tail cuff blood pressure at 11-12 months of age relative to control mice





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
01/04/2022
MGI 6.17
The Jackson Laboratory